The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders Meeting Abstract


Authors: Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; Neylon, E.; Hamelers, R.; Zelenetz, A.; Myers, T. J.; Boral, A. L.; O'Connor, O. A.
Abstract Title: The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders
Meeting Title: 48th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 108
Issue: 11 Pt. 1
Meeting Dates: 2006 Dec 9-12
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2006-11-01
Start Page: 781A
Language: English
ACCESSION: WOS:000242440003548
PROVIDER: wos
PUBMED: 17139767
Notes: --- - Meeting Abstract: 2759 - 48th Annual Meeting of the American-Society-of-Hematology - DEC 09-12, 2006 - Orlando, FL - Part 1 - "Source: Wos"
MSK Authors
  1. Carol Portlock
    183 Portlock
  2. Craig Moskowitz
    378 Moskowitz
  3. Ariela Noy
    211 Noy
  4. Maria Lia Palomba
    132 Palomba
  5. Steven M Horwitz
    369 Horwitz
  6. Andrew D Zelenetz
    563 Zelenetz
  7. Paul Hamlin
    177 Hamlin
  8. David J Straus
    218 Straus
  9. Ellen Neylon
    10 Neylon